Literature DB >> 1501422

Impaired metabolism of high density lipoprotein in uremic patients.

T Shoji1, Y Nishizawa, H Nishitani, M Yamakawa, H Morii.   

Abstract

We measured lipoproteins, apolipoproteins, lipoprotein lipase (LPL), hepatic triglyceride lipase (HTGL), lecithin: cholesterol acyltransferase (LCAT) and parameters of calcium metabolism to evaluate the roles of these enzymes and hypertriglyceridemia for impaired high-density lipoprotein (HDL) metabolism in chronic renal failure, and to examine the impact of altered calcium homeostasis on the lipoprotein-regulating enzymes. The subjects were 25 healthy volunteers and 66 uremic patients, 24 treated with hemodialysis (HD) and 42 with continuous ambulatory peritoneal dialysis (CAPD). Lipoprotein analysis revealed: (1) reduction in HDL cholesterol especially in HDL2 subfraction; (2) increase in HDL triglyceride; and (3) decreased ratio of HDL2 cholesterol to HDL3 cholesterol in both HD and CAPD patients. Simple regression analysis showed: (1) a positive correlation between VLDL triglyceride and triglyceride/cholesterol ratio of HDL; (2) positive correlations of LPL level in post-heparin plasma to cholesterol concentrations in HDL2, HDL3 and total HDL, and to apolipoproteins A-I and A-II; and (3) inverse correlations of HTGL to HDL2 cholesterol and to the ratio of HDL2 cholesterol/HDL3 cholesterol. Multiple regression analysis of HDL cholesterol indicated positive association with LPL and inverse correlation with VLDL triglyceride. Four variables including LPL, HTGL, LCAT and VLDL triglyceride explained 51.5% of the variation of HDL cholesterol. HDL2 cholesterol was associated positively with LPL and negatively with VLDL triglyceride in the model. HDL3 cholesterol was associated positively with LPL, HTGL and LCAT and inversely with VLDL triglyceride. Stepwise multiple regression analysis indicated that independent predictors of HTGL were gender, parathyroid hormone levels by a mid-portion assay, ionized calcium and age, and that those of LCAT were ionized calcium and age.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501422     DOI: 10.1038/ki.1992.238

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.

Authors:  Nosratola D Vaziri; Jun Yuan; Zhenmin Ni; Susanne B Nicholas; Keith C Norris
Journal:  Clin Exp Nephrol       Date:  2011-10-19       Impact factor: 2.801

Review 2.  Osteoporosis and atherosclerosis in chronic renal failure.

Authors:  Y Nishizawa; H Morii
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Serum metabolomic profiles from patients with acute kidney injury: a pilot study.

Authors:  Jinchun Sun; Melissa Shannon; Yosuke Ando; Laura K Schnackenberg; Nasim A Khan; Didier Portilla; Richard D Beger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-06       Impact factor: 3.205

Review 4.  HDL metabolism and activity in chronic kidney disease.

Authors:  Nosratola D Vaziri; Mohamad Navab; Alan M Fogelman
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

5.  Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo.

Authors:  Gunther Marsche; Sasa Frank; Andelko Hrzenjak; Michael Holzer; Sabine Dirnberger; Christian Wadsack; Hubert Scharnagl; Tatjana Stojakovic; Akos Heinemann; Karl Oettl
Journal:  Circ Res       Date:  2009-01-29       Impact factor: 17.367

6.  Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

Authors:  Madeleine V Pahl; Zhenmin Ni; Lili Sepassi; Hamid Moradi; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

Review 7.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 8.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

9.  Reverse cholesterol transport pathway in experimental chronic renal failure.

Authors:  Hamid Moradi; Jun Yuan; Zhemin Ni; Keith Norris; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2009-03-24       Impact factor: 3.754

Review 10.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.